Monday, 26 Aug 2019

You are here

CDC Top 15 Most Common Opioid Overdose Drugs

The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.

From 1999 through 2016, the age-adjusted rate of drug overdose deaths in the United States more than tripled from 6.1 per 100,000 to 19.8 per 100,000 according to the report.

The top 15 drugs were identified based on the number of drug overdose deaths per referent drug category. While the ranking changed from year to year, the top 10 drugs involved in overdose deaths remained consistent throughout the 6-year period. The top 10 drugs belonged to three drug classes:

  • Opioids: fentanyl, heroin, hydrocodone, methadone, morphine, and oxycodone
  • Benzodiazepines: alprazolam and diazepam
  • Stimulants: cocaine and methamphetamine 

In 2011, oxycodone ranked first, while heroin and fentanyl were ranked first during 2012 to 2015 and in 2016, respectively.

Cocaine consistently ranked second or third during the study period. The age-adjusted rate of drug overdose deaths involving heroin more than tripled from 2011 through 2016, as did the rate of drug overdose deaths involving methamphetamine.

Each year from 2013 to 2016, the rate of drug overdose deaths involving fentanyl and fentanyl analogs doubled (0.6, 1.3, 2.6, and 5.9 per 100,000 in 2013, 2014, 2015, and 2016, respectively).

This report shows that the most frequent drugs mentioned varied over time and by intent of death (i.e., unintentional drug overdose, suicide by drug overdose, and overdose death of undetermined intent). Results from the literal text analysis also confirm that many drug overdose deaths involve multiple drugs.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.

FDA Adds Boxed Warning to Sleep Drugs

The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not fully awake) when taking sleep medications. These complex sleep behaviors have also resulted in deaths.